Da IGF- 1- mangel er sjælden, blev INCRELEX udpeget som "lægemiddel til sjældne sygdomme" den 22. maj 2006.
Because the number of patients with primary IGF-1 deficiency is low, the disease is considered ‘ rare’, and INCRELEX was designated an ‘ orphan medicine ’ (a medicine used in rare diseases) on 22 May 2006.